Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
Status:
Terminated
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying the side effects and how well sorafenib works in
treating patients with metastatic or unresectable kidney cancer.